Mobia Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
65.8%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$53.5Mnext fiscal year
FY EPS (est.)
-$2.46next fiscal year
Monitoring Framework
Key Performance Indicators
Vivistim IPG Unit Sales Growth Quarterly109.0%Target: Maintain triple-digit year-over-year growth to support commercial scaling
Quarterly Revenue Quarterly12.1MTarget: 78150000 annually for FY 2027
Direct Sales Force Size Annually83.0Target: Expand direct sales force and territory coverage post-IPO
Watch Items
- CMS Reimbursement Status under New Technology APC 1580Trigger: CY 2027 proposed hospital outpatient payment rate of ~$45,000Action: Monitor final CMS rulemaking and track claims data collection over the next 2-3 years to secure permanent reimbursement codes.
- Operating Cash Burn and Net LossesTrigger: Q1 2026 net loss of $17.74 million and accumulated deficit of $175.5 millionAction: Evaluate operating leverage and commercial efficiency as direct sales force scales to mitigate widening losses.
Research as of 29 Mar 2026